株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

新興国市場の生物製剤市場:商業的可能性の実現化の機会と、残された課題

Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome

発行 CBR Pharma Insights 商品コード 290386
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
新興国市場の生物製剤市場:商業的可能性の実現化の機会と、残された課題 Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome
出版日: 2012年09月15日 ページ情報: 英文 59 Pages
概要

これまで、生物製剤はその製造工程の複雑さ・高コスト・長期化から途上国での市場拡大が難しい状況が続きました。しかし、近年になって世界的な市場成長が続き、2010年には1300億米ドルの規模に達しています。特にBRIC諸国では潜在的な市場規模は非常に大きく、2015年には世界の生物製剤市場の25%を占めると予想されています。

当レポートでは、新興国市場における生物製剤市場の動向と、関連企業のとるべき戦略について分析し、生物製剤の定義・概要や全世界の市場動向、新興国の生物製剤市場の概況、BRIC(ブラジル・ロシア・インド・中国)市場の詳細動向、今後解決すべき課題、主要企業のプロファイルと動向、今後の市場の方向性などを調査・考察して、その結果を概略以下の構成でお届けします。

エグゼクティブ・サマリー

分析手法

生物製剤の概要

  • 定義
  • 様々な種類の生物製剤
  • 世界の生物製剤市場

新興国市場での生物製剤:要点

  • 主要市場の現状
  • 生物製剤の成長見通し
  • バイオシミラーと新興市場国
  • 生物製剤に関する規制
  • BRIC諸国の詳細分析

新興国市場での生物製剤の利用拡大に関する主な課題

  • 診断検査
  • 生物製剤のコストの高さ
  • 生物製剤利用に関する他の障壁

新興国市場の生物製剤市場における主要企業

  • BRIC諸国の競争環境の概要と主な企業活動

付録

  • 追加的情報
  • 参考文献
目次
Product Code: CBRSV037

Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacture an expensive and lengthy process which has hindered uptake in many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010.

Of the emerging markets, the BRIC markets offer the greatest potential for pharmaceutical growth, especially in biologics which represent a relatively untapped market in these countries. It is expected the BRIC markets will account for over 25% of global biologic revenues by 2015.

The report, "Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome" has been written to support corporate strategy, new product development, business development, R&D, and brand teams through its analysis of the biologic trends being seen and the innovations taking place in this high growth market place. This report will support the corporate strategies and key decisions being made around emerging market expansion, and future opportunities, and the challenges, which exist.

Scope

  • Biologics overview Definition, types of biologics and the global biologics market
  • Biologics in emerging markets - key facts
  • Analysis of BRIC countries
  • Key challenges
  • Key biologics players in emerging markets
  • Overviews of the competitive landscapes and key activities in the BRIC countries

Key Reasons to Purchase

  • Use this report to understand how the biologics market is expected to develop in the emerging markets and the key growth drivers behind the forecasted changes
  • This report provides an overview of the current biologics landscape in each of the BRIC markets, along with expected challenges and potential areas of growth in the near term
  • Understand how key factors, such as diagnostic testing, high price points and negative perceptions of biologics, are hindering their wider use in some emerging markets
  • Benefit from CBR's in-depth analysis of the competitive landscape for biologics in the BRIC markets, including recent activities of both local and multinational companies and the prospects for collaboration moving forward
  • Access our assessment of how biosimilars are boosting the biologics sector within emerging markets and why they have been so quick to take off in these regions compared to the US and EU market

Table of Contents

  • Executive summary
  • Methodology
  • Biologics overview
    • Definition
    • Different types of biologics
    • The global biologics market
  • Biologics in emerging markets - key facts
    • Snapshot of key markets
    • Biologics growth prospects
    • Biosimilars and the emerging markets
    • Regulation of biologics
    • BRIC countries in focus
  • Key challenges to greater use of biologics in the emerging markets
    • Diagnostic testing
    • The high cost of biologics
    • Other hurdles to biologic use
  • Who are the key biologics players in emerging markets?
    • Overviews of the competitive landscapes and key activities in the BRIC countries
  • Appendix
    • Supplemental information
    • List of sources
Back to Top